N/A N=146 Infant and Parent Shared Book Reading
Individual, Category, and No-label Conditions
Primary: Infant Visual Attention — .533; .358; .377; .544 Proportion of Visual Attention Duration — p==.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer
Locally Advanced Rectal Cancer
Primary: Number of Participants Who Had a Dose Limiting Toxicity (DLT) Following Treatment With Enadenotucirev and Chemoradiotherapy (Capecitabine and Radiation) at 1 of 4…
Phase 2 N=153 Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
Type 2 Diabetes Treated With Insulin
Primary: Change in HbA1c — -0.20; -0.53; -0.31 % of glycated haemoglobin — p=0.0039
Phase 2 N=159 Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
PTSD
Primary: Newly Treatment Emergent Adverse Events — 37; 20; 14 Participants
Phase 3 N=1,003 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Carcinoma, Nonsquamous Non-small-cell Lung
Primary: Progression-free Survival (PFS) — 7.1; 8.3 Months — p=0.8721
Phase 2 N=15 Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Advanced Solid Tumor · IDH1 Mutation · Glioma
Primary: Best Overall Response — 1; 6 Participants
Phase 2 N=42 Karolinska Interventional Study of Mammograhic Density (Karisma-1)
Breast Cancer · Mammographic Density
Primary: Mammographic Breast Density — -3.3; -2.5 percentage of breast area
N/A N=2,233 SEARCH SAPPHIRE Phase A: A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East Africa
HIV · Hypertension · Alcohol Drinking
Primary: Prevention Coverage Defined as Percentage of Follow-up Months That the Participant Used Either PrEP or PEP — 47.5; 18.3 Percentage of months
N/A N=150 Incorporating Nutrition, Vests, Education, and Strength Training in Bone Health (INVEST in Bone Health)
Weight Loss · Bone Health
Primary: Change in Total Hip Trabecular Volumetric Bone Mineral Density (vBMD) — -0.002; -0.002; -0.003 mg/cm3
N/A N=81 Translational Research to Inform Interventions for Challenging Behavior
Behavior and Behavior Mechanisms
Primary: Peak Response Rate During Extinction — 1.58; 0.85; 1.3; 0.43 Proportion of baseline (frequency)
N/A N=66 Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
Breast Carcinoma
Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…
N/A N=50 Dual-Tracer Theranostic PET
Neuroendocrine Tumors · Prostate Cancer
Primary: Completion of Two PET/CT Scans Per Patient as Dictated by Assigned Arm — 30; 30; 40 PET/CT scans
Phase 1 N=12 Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers
Tuberculosis
Primary: To Quantify BCG Recoverable From Bronchial Sample — 0; 0; 0; 0 Volunteers with detectable BCG
N/A N=15 Confirmatory Study to Assess the V Needle in End-Stage Renal Disease Patients During In-Clinic Hemodialysis
End Stage Renal Disease
Primary: Percentage of Successful Hemodialysis Sessions — 100; 98.9 percentage of successful sessions — p=.008
Phase 2 N=16 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Progression Free Survival (PFS) — 255.921 days to progression